Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases

dc.contributor.author Smith, Pete K
dc.contributor.author Price, David B
dc.contributor.author Harvey, Richard John
dc.contributor.author Carney, Andrew Simon
dc.contributor.author Kritikos, Vicky
dc.contributor.author Bosnic-Anticevich, Sinthia Z
dc.contributor.author Christian, Louise
dc.contributor.author Skinner, Derek
dc.contributor.author Carter, Victoria
dc.contributor.author Durieux, Alice Marie Sybille
dc.date.accessioned 2017-06-01T00:13:33Z
dc.date.available 2017-06-01T00:13:33Z
dc.date.issued 2017-05-09
dc.description This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). en
dc.description.abstract Purpose: There is a relative paucity of research regarding medication expenditure associated with multiple-therapy use for rhinitis in Australia. To describe 1) the nature and extent of multiple-therapy use for rhinitis in Australia using data on therapies purchased with prescription or over-the-counter (OTC) and 2) additional costs incurred by multiple-therapy use compared with intranasal corticosteroid (INCS) therapy alone. Patients and methods: A retrospective observational study was carried out using a database containing anonymous pharmacy transaction data available from 20% of pharmacies in Australia that links doctor prescriptions and OTC purchase information. Pharmacy purchases of at least one prescription or OTC rhinitis treatment, with or without additional asthma/chronic obstructive pulmonary disease (COPD) therapy, by patients during 2013 and 2014 were assessed. Results: In total, 4,247,193 prescription and OTC rhinitis treatments were purchased from 909 pharmacies over 24 months. The majority of rhinitis therapy transactions were single-therapy purchases without additional asthma/COPD therapy. Of the single therapies purchased, 73% were oral antihistamines (OAHs) and 15% were INCS therapy. Dual-therapy purchases of INCSs and OAHs accounted for 40% of multiple-therapy purchases. Patients frequently purchased OAHs, nonsteroidal nasal sprays, and eye drops for allergic conjunctivitis alongside INCSs, resulting in higher financial costs (up to AU$21 per treatment episode) compared with INCS monotherapy. Conclusion: This study highlighted the significant burden posed on community pharmacy to address the needs of people with rhinitis symptoms, and the failure to translate the evidence that INCSs are the most effective monotherapy for moderate to severe and/or persistent rhinitis into clinical practice in light of the lack of evidence supporting combination of INCS and OAH therapy. Health care professional engagement, especially at the pharmacy level, will be extremely important if we wish to ensure that the purchase of rhinitis treatment is in accordance with guidelines and that their use is optimal. en
dc.identifier.citation Smith, P., Price, D., Harvey, R., Carney, A. S., Kritikos, V., Bosnic-Anticevich, S. Z., ... & Durieux, A. M. S. (2017). Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases. Journal of Asthma and Allergy, 10, 153. en
dc.identifier.doi https://doi.org/10.2147/JAA.S128431 en
dc.identifier.issn 1178-6965
dc.identifier.uri http://hdl.handle.net/2328/37241
dc.language.iso en
dc.oaire.license.condition.license CC-BY-NC
dc.publisher Dove Press en
dc.rights © 2017 The authors en
dc.rights.holder The authors en
dc.subject community pharmacy en
dc.subject intranasal corticosteroids en
dc.subject oral antihistamines en
dc.subject over-the-counter en
dc.subject prescription en
dc.subject rhinitis en
dc.subject therapy en
dc.title Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases en
dc.type Article en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Smith_Medication_P2017.pdf
Size:
324.23 KB
Format:
Adobe Portable Document Format
Description:
Publisher version
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.84 KB
Format:
Item-specific license agreed upon to submission
Description: